A large Pharmaceutical company, headquartered in the US, wanted DelveInsight to support them by providing a detailed conference coverage of the oncology drug for the indication HER2 negative breast cancer published during ASCO 2022, including the product description, research and developmental activities, product milestones, future plans, and KOL insights.